PDF(Pubmed)
Abstract：
UNASSIGNED: A major modifiable risk factor for atherosclerotic cardiovascular disease is abnormalities in lipid and lipoprotein metabolism which are frequently seen in HIV as well as its treatment. Apo-E is a protein that is important in plasma lipid homeostasis and its genetic alleles have been shown to contribute to lipid abnormalities. We examined for the effect of Apo-E gene polymorphisms on plasma lipid levels in PLHIV on protease inhibitor therapy.
UNASSIGNED: This was a cross-sectional study conducted among adult persons living with HIV. Lipid profile, Apo-B and Apo-A were measured in fasting plasma. Amplification and analysis of Apo-E genotypes were determined using the Seeplex Apo-E ACE genotyping kit. Differences in quantitative values were compared with non-parametric analysis methods.
UNASSIGNED: Eighty-four persons were recruited into the study, 75% of whom were virally suppressed. The 3 homozygous genotypes had significantly different levels of low-density lipoprotein cholesterol (LDL-C), Apolipoprotein B (Apo-B) and Apolipoprotein A1 (Apo-A1). Persons with apo ε2/ε2 had higher LDL-C compared to those with apo ε3/ε3 (3.26 (3.61) mmol/L vs. 2.76 (1.28) mmol/L, p = 0.010). Those with apo ε4/ε4 had lower Apo-A1 compared to those with apo ε3/ε3 (0.84 (0.48) g/dL vs. 1.27 (0.70) g/dL, p =0.009). Compared with the same group, the heterozygous genotype, apo ε2/ε3 had lower triglyceride levels :1.33 (0.65) mmol/ L vs. 1.86 (1.11) mmol/L, p = 0.045.
UNASSIGNED: Polymorphisms in the Apo-E gene may have significant influences on plasma lipid and apolipoprotein levels in PLHIV on PI therapy. This may have implications for the assessment of risk for cardiovascular disease.
UNASSIGNED: This was a cross-sectional study conducted among adult persons living with HIV. Lipid profile, Apo-B and Apo-A were measured in fasting plasma. Amplification and analysis of Apo-E genotypes were determined using the Seeplex Apo-E ACE genotyping kit. Differences in quantitative values were compared with non-parametric analysis methods.
UNASSIGNED: Eighty-four persons were recruited into the study, 75% of whom were virally suppressed. The 3 homozygous genotypes had significantly different levels of low-density lipoprotein cholesterol (LDL-C), Apolipoprotein B (Apo-B) and Apolipoprotein A1 (Apo-A1). Persons with apo ε2/ε2 had higher LDL-C compared to those with apo ε3/ε3 (3.26 (3.61) mmol/L vs. 2.76 (1.28) mmol/L, p = 0.010). Those with apo ε4/ε4 had lower Apo-A1 compared to those with apo ε3/ε3 (0.84 (0.48) g/dL vs. 1.27 (0.70) g/dL, p =0.009). Compared with the same group, the heterozygous genotype, apo ε2/ε3 had lower triglyceride levels :1.33 (0.65) mmol/ L vs. 1.86 (1.11) mmol/L, p = 0.045.
UNASSIGNED: Polymorphisms in the Apo-E gene may have significant influences on plasma lipid and apolipoprotein levels in PLHIV on PI therapy. This may have implications for the assessment of risk for cardiovascular disease.
摘要：
动脉粥样硬化性心血管疾病的主要可改变的危险因素是脂质和脂蛋白代谢异常，这在HIV及其治疗中很常见。Apo-E是一种在血浆脂质稳态中很重要的蛋白质，其遗传等位基因已被证明有助于脂质异常。我们研究了Apo-E基因多态性对蛋白酶抑制剂治疗PLHIV血浆脂质水平的影响。
■这是一项对感染艾滋病毒的成年人进行的横断面研究。脂质轮廓,在空腹血浆中测量Apo-B和Apo-A。使用SeeplexApo-EACE基因分型试剂盒测定Apo-E基因型的扩增和分析。将定量值的差异与非参数分析方法进行比较。
■招募了84人参加研究，75%的人被病毒抑制。3个纯合基因型的低密度脂蛋白胆固醇(LDL-C)水平差异显著,载脂蛋白B(Apo-B)和载脂蛋白A1(Apo-A1)。apoε2/ε2患者的LDL-C高于apoε3/ε3患者（3.26（3.61）mmol/Lvs.2.76(1.28)mmol/L,p=0.010)。与apoε3/ε3相比，apoε4/ε4的Apo-A1较低（0.84（0.48）g/dL与1.27（0.70）g/dL，p=0.009)。与同组相比,杂合基因型，载脂蛋白ε2/ε3的甘油三酯水平较低：1.33（0.65）mmol/Lvs.1.86(1.11)mmol/L,p=0.045。
■Apo-E基因的多态性可能对PI治疗的PLHIV中的血浆脂质和载脂蛋白水平有重大影响。这可能对评估心血管疾病的风险有影响。
■这是一项对感染艾滋病毒的成年人进行的横断面研究。脂质轮廓,在空腹血浆中测量Apo-B和Apo-A。使用SeeplexApo-EACE基因分型试剂盒测定Apo-E基因型的扩增和分析。将定量值的差异与非参数分析方法进行比较。
■招募了84人参加研究，75%的人被病毒抑制。3个纯合基因型的低密度脂蛋白胆固醇(LDL-C)水平差异显著,载脂蛋白B(Apo-B)和载脂蛋白A1(Apo-A1)。apoε2/ε2患者的LDL-C高于apoε3/ε3患者（3.26（3.61）mmol/Lvs.2.76(1.28)mmol/L,p=0.010)。与apoε3/ε3相比，apoε4/ε4的Apo-A1较低（0.84（0.48）g/dL与1.27（0.70）g/dL，p=0.009)。与同组相比,杂合基因型，载脂蛋白ε2/ε3的甘油三酯水平较低：1.33（0.65）mmol/Lvs.1.86(1.11)mmol/L,p=0.045。
■Apo-E基因的多态性可能对PI治疗的PLHIV中的血浆脂质和载脂蛋白水平有重大影响。这可能对评估心血管疾病的风险有影响。
